Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies - Wikidata - awgldk - TriplyDB

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

http://www.wikidata.org/entity/Q34065963

about

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials Striving for optimal bronchodilation: focus on olodaterol Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease Long-term safety of tiotropium delivered by Respimat® SoftMist™ Inhaler: patient selection and special considerations Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD.Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.Pragmatic research and outcomes in asthma and COPD Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler.Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD.Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.Tiotropium formulations and safety: a network meta-analysis Optimizing bronchodilation in the prevention of COPD exacerbations Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.Long-term outcomes in chronic obstructive pulmonary disease patients: exploring the effects of inhalatory devices and their influence on the outcome.Impact and prevention of severe exacerbations of COPD: a review of the evidence.Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap

P2860

Q24613889-4E43ED20-7854-4D93-8883-A0F9AA947DFD Q26752887-E98D9E0A-96A0-48A8-81DA-AC4259DFA663 Q26823339-FD9E3BFA-7C9E-4D50-8E81-BFF8E0CE048D Q28067579-65471108-BB97-44BF-AA14-CD7F207CB4ED Q30620671-68789CCF-355E-4C6A-9493-FAFCFDF59627 Q30877371-3BE10724-7184-4EFD-86DA-2425965CDE32 Q34133948-960D1B83-9C4C-4F8D-89A1-1B21E0F5EF95 Q34677811-68BD3A25-5B06-465B-8E0C-2DB7614E336E Q34721292-6E26D191-2C42-48CE-9812-F2CF4373BEAA Q35131472-76A8EA8C-C4F7-4675-9301-98D970C7E1A9 Q35675649-0803791A-8AB9-43D7-9A33-56F398797429 Q35774959-FDCE962C-2B13-42A2-AB32-728325101AB9 Q35999260-44C2B153-C51E-4D5E-B1CE-BE0A06AE79DC Q36063173-95B7B696-14D3-4BAE-8C1E-5110F80E514B Q36652462-5896B4DB-ACDA-4348-8A7E-DA5E6B45489C Q36752114-E579841A-BA9E-4944-BD34-FB0DF4B226A4 Q37170227-B9AB0254-5464-4BEA-B3A8-B13C2735C2D1 Q37300877-812374B0-D557-4AC3-A807-B566702B4592 Q37701125-398567A8-9919-4AC0-AE17-CD0EC12F3CBF Q38604644-0F433A28-B265-457D-B50B-318C6CAFBE4F Q38639661-D81FB656-6464-4A63-BF6B-9055B5DD8EEB Q38690660-2181F0C4-59CB-4060-BD35-6DCF2418E37D Q39137733-89FC1940-2DB2-4373-8533-ECA58063EA1A Q39386571-1BC0AC64-4E1A-4774-8653-622E6132D155 Q39399389-9C817F38-5C6E-4CB8-B04F-18ACB9F552A1 Q40706819-AED09097-5EA1-4E8F-A765-6011EB3D62C8 Q45803920-9D4F8504-2464-4DDD-A4E1-DDB727BAAA5F Q55120067-F2CC7C22-E0D6-4103-B15C-F228EDEBC265 Q57817177-FD0E55C3-7113-4F11-A3C5-24BB2BB6679D Q58806313-8DD57410-F516-4A2F-930A-4C51980B0D9C

P2860

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

http://www.wikidata.org/entity/Q34065963

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@ast

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@en

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@nl

type

label

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@ast

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@en

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@nl

prefLabel

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@ast

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@en

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@nl

P1433

Q34065963-1EAD996B-521E-46B4-97B0-7AEEC6264AF2

P1476

Q34065963-24B194DC-23D9-4CA9-81EF-8DA32888E4BF

P2093

Q34065963-0345B9B9-D757-400F-B265-2F61B5CF2D9C

Q34065963-23F6509D-652F-47EA-B1CB-2084EEC09881

Q34065963-69925866-7B0F-4A2C-9271-6F16551847C0

Q34065963-74AA391F-EA00-4DA9-A1AA-4AAC90B9E63F

Q34065963-AB4C7A13-3815-4E3C-B91A-23DB10BE3A43

Q34065963-AF44BADC-A275-410D-95F5-6A0B9561E91D

Q34065963-BCE7894A-74A2-44D1-9BE1-3A86BCA1A6DF

Q34065963-EC9F3D6B-1FE3-4E08-877C-10B2C835CC16

P2860

Q34065963-00D0120D-8C31-4AB3-901C-0B959E704477

Q34065963-06579FFB-193B-4955-8E87-D3240C9508C6

Q34065963-091D9828-5C30-4797-8056-40971276F7AC

Q34065963-10C90EE8-1C10-400C-8AF0-742EACE69837

Q34065963-144830D3-4202-424E-A7CA-FE6021FFDCF0

Q34065963-17A94B92-8F5D-475F-8D45-1F016B00A226

Q34065963-25BB5234-4B04-45D5-BE60-537CBCAA1AAC

Q34065963-346FE884-EBC8-4E55-AFE9-DCFE7246C497

Q34065963-35E72C84-3EED-4D79-BC32-07690760DC5B

Q34065963-37183C70-8534-41C1-8997-CC8B8761F69B

P304

Q34065963-C9F84153-BAEC-4728-AD6D-3A6E1D938B59

P31

Q34065963-AC0F1EBF-FEDD-46D8-AD71-16186E68304E

P407

Q34065963-1B45E90E-BC18-44CC-A495-B9834262A9A8

P478

Q34065963-CA5A85D9-2118-44AA-90B1-2ECBB692E33C

P50

Q34065963-283E4F38-A8A7-4CD4-A915-41BC3B7F8DB9

P577

Q34065963-6CB5F48D-4DA1-4AEA-BDAC-962C899DDAEA

P698

Q34065963-525C412B-7674-43A3-8799-FC918D82DBAE

P921

Q34065963-231F0791-99C8-4994-AC81-66FC97FBF338

P932

Q34065963-885ECE77-4228-47E7-850A-11D389B25F84

P1433

International Journal of Chronic Obstructive Pulmonary Disease

P1476

Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies

@en

P2093

Bernd Disse

http://www.w3.org/2001/XMLSchema#string

Dan Massey

http://www.w3.org/2001/XMLSchema#string

Dave Singh

http://www.w3.org/2001/XMLSchema#string

David Smith

http://www.w3.org/2001/XMLSchema#string

Demetri Pavia

http://www.w3.org/2001/XMLSchema#string

Eric Bateman

http://www.w3.org/2001/XMLSchema#string

Lesley Towse

http://www.w3.org/2001/XMLSchema#string

Rick Hodder

http://www.w3.org/2001/XMLSchema#string

P2860

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.

Optimizing the in vitro performance of Respimat.

How should health-related quality of life be assessed in patients with COPD?

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.

The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma.

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

P304

197-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20714373

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

2921687

http://www.w3.org/2001/XMLSchema#string